Ubang, Rowell F.
HRN: 21-07-50 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/10/2023
OXACILLIN 500MG (VIAL)
06/10/2023
06/17/2023
IV
400mg
Q6
Staphylococcal Infection(Impetigo)
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes